Publications by authors named "G Policastro"
Lactic acid (LA) is a versatile, optically active compound with applications across the food, cosmetics, pharmaceutical, and chemical industries, largely driven by its role in producing biodegradable polylactic acid (PLA). Due to its abundance, lignocellulosic biomass is a promising and sustainable resource for LA production, although media derived from these matrices are often rich in xylose and contain growth inhibitors. This study investigates LA production using a xylose-rich medium derived from DC stalks treated through steam explosion and enzymatic hydrolysis.
View Article and Find Full Text PDFArticle Synopsis
- * Treatment focuses on reducing spleen size and alleviating symptoms, with patients evaluated as lower or higher risk for transplant eligibility; those not eligible usually receive long-term JAK inhibitor therapy.
- * Newer JAK inhibitors and combination treatments are under investigation to address the limitations of current therapies, such as limited efficacy and adverse effects, highlighting the need for ongoing research in this area.
Article Synopsis
- This study examined the effects of D-VTd induction therapy on recovery after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (NDMM).
- Sixty patients received D-VTd while 80 others received VTd as a control, with results showing that D-VTd led to a slightly longer time for neutrophil and platelet recovery.
- Despite delayed engraftment in the D-VTd group and a higher incidence of febrile neutropenia, the study concluded that D-VTd does not negatively affect overall transplant safety outcomes.
Article Synopsis
- Acute myeloid leukemia (AML) treatment has improved, but many patients still experience relapse, highlighting the need for effective maintenance therapies post-chemotherapy or stem cell transplants.* -
- This review examines the current debates and findings regarding these maintenance therapies for AML, including choice of drugs for optimal patient outcomes.* -
- Experts recommend specific FLT3 inhibitors like midostaurin or quizartinib for FLT3-positive AML patients, while the duration of maintenance therapy remains unclear, needing further research.*